Centessa Pharmaceuticals plc (NASDAQ:CNTA) Shares Acquired by Lord Abbett & CO. LLC

Lord Abbett & CO. LLC boosted its stake in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 63.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 440,495 shares of the company's stock after purchasing an additional 171,290 shares during the quarter. Lord Abbett & CO. LLC owned about 0.33% of Centessa Pharmaceuticals worth $7,378,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its holdings in shares of Centessa Pharmaceuticals by 29.1% in the 4th quarter. GAMMA Investing LLC now owns 3,837 shares of the company's stock valued at $64,000 after buying an additional 865 shares in the last quarter. Barclays PLC boosted its stake in Centessa Pharmaceuticals by 1,414.9% in the fourth quarter. Barclays PLC now owns 5,302 shares of the company's stock valued at $89,000 after acquiring an additional 4,952 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Centessa Pharmaceuticals by 39.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 18,909 shares of the company's stock worth $317,000 after purchasing an additional 5,316 shares in the last quarter. XTX Topco Ltd lifted its holdings in shares of Centessa Pharmaceuticals by 122.9% during the 4th quarter. XTX Topco Ltd now owns 22,680 shares of the company's stock valued at $380,000 after purchasing an additional 12,506 shares during the last quarter. Finally, Voya Investment Management LLC acquired a new stake in shares of Centessa Pharmaceuticals in the 4th quarter worth $497,000. Hedge funds and other institutional investors own 82.01% of the company's stock.

Centessa Pharmaceuticals Stock Performance

CNTA traded up $0.11 during trading on Friday, reaching $13.61. 749,858 shares of the company's stock were exchanged, compared to its average volume of 616,431. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. Centessa Pharmaceuticals plc has a 1 year low of $7.75 and a 1 year high of $19.09. The company's fifty day simple moving average is $14.17 and its 200-day simple moving average is $15.78. The stock has a market capitalization of $1.81 billion, a P/E ratio of -8.90 and a beta of 1.53.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last posted its earnings results on Monday, March 24th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.38) by $0.04. As a group, research analysts predict that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

CNTA has been the subject of a number of research analyst reports. TD Cowen started coverage on Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They issued a "buy" rating for the company. Morgan Stanley reaffirmed an "overweight" rating and issued a $27.00 price objective on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Guggenheim reiterated a "buy" rating and issued a $28.00 target price on shares of Centessa Pharmaceuticals in a research note on Wednesday, March 26th. Finally, Piper Sandler assumed coverage on shares of Centessa Pharmaceuticals in a research note on Monday, March 31st. They set an "overweight" rating and a $38.00 price target on the stock. Eight analysts have rated the stock with a buy rating, According to MarketBeat, Centessa Pharmaceuticals presently has a consensus rating of "Buy" and an average target price of $27.71.

Insider Transactions at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider Karen M. Anderson sold 6,471 shares of the company's stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $16.86, for a total value of $109,101.06. Following the sale, the insider now owns 54,322 shares in the company, valued at approximately $915,868.92. This represents a 10.64 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, General Counsel Iqbal J. Hussain sold 2,080 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $14.01, for a total transaction of $29,140.80. Following the transaction, the general counsel now directly owns 105,386 shares of the company's stock, valued at approximately $1,476,457.86. This trade represents a 1.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 219,824 shares of company stock worth $3,581,039 over the last quarter. 11.59% of the stock is currently owned by insiders.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.